Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Basel, May 31, 2024 – Novartis today presents positive results from the pivotal Phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology (ASCO) meeting
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
06:01pm, Thursday, 30'th May 2024
Basel, May 31, 2024 – Novartis today announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in chronic sponta
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
02:45pm, Wednesday, 29'th May 2024
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and t
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
01:31pm, Monday, 27'th May 2024
Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.
Novartis: Buy This Blue-Chip Dividend Stock On Sale Now
07:00am, Monday, 27'th May 2024
Novartis is a business that has shown tremendous resiliency, operating for hundreds of years. The multinational Swiss pharmaceutical topped the analyst consensus for revenue and core EPS in Q1. Novart
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical
This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
11:54am, Thursday, 23'rd May 2024
Targeted radiopharmaceuticals has caught the eye of big pharma. The therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.
SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointme
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
07:15am, Thursday, 16'th May 2024
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stoc
Basel, May 15, 2024 – Novartis will present data from more than 60 abstracts, including investigator-initiated trials at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the
3 Magnificent Stocks That Are Passive Income Machines
06:30am, Tuesday, 14'th May 2024
Eli Lilly is an ideal stock for growth and dividends. AbbVie is a Dividend King with a bright future.
Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer
09:12am, Tuesday, 07'th May 2024
WAYNE, Pa.--(BUSINESS WIRE)-- #CLI--Cagent Vascular announced today that Brian Walsh has been named Chief Executive Officer by the Cagent Vascular Board of Directors. He has served as Chairman of the
2 Magnificent Dividend Stocks to Hold for the Next Decade
02:25pm, Sunday, 05'th May 2024
Novartis has increased its payout for 27 consecutive years thanks to a robust, innovation-driven business. Visa is an undisputed leader in its niche and still has strong growth prospects.
10 Sleep-Well-At-Night Dividend Aristocrats Perfect For Whatever's Coming Next
07:00am, Friday, 03'rd May 2024
The stock market is unpredictable, and even professionals struggle to understand it. Stocks have historically been the best-performing asset, but short-term returns are influenced by sentiment, moment
